FDA Accepts Merck’s NDA for Fixed-Dose Combination of Raltegravir with Lamivudine

Dateline City: WHITEHOUSE STATION, N.J. If Approved, Fixed-Dose Combination Would Be Used with Other Antiretroviral Agents for the Treatment of HIV-1 in Adults, Adolescents and Certain Pediatric Patients Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for a fixed-dose combination (FDC) of raltegravir with lamivudine for the treatment of HIV-1 infection (MK-0518B) has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Language: English read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Source Type: news